

# MTN-013/IPM 026

## Study-Specific Procedures Manual

### Table of Contents

---

#### Section 1. Introduction

1.1	Sources of Procedural Information.....	1-1
1.2	Investigator Responsibilities .....	1-1
1.3	Study Activation Process.....	1-2

#### Section 2. Protocol

#### Section 3. Documentation Requirements

3.1	Essential Documents .....	3-1
3.2	Participant Case History Documentation .....	3-2
	3.2.1 Case History Contents .....	3-2
	3.2.2 Concept of Source Data and Source Documentation .....	3-2
	3.2.3 Document Organization .....	3-4
3.3	Study Product Accountability, Chain of Custody, and Dispensing Documentation .....	3-6
3.4	Record Retention Requirements.....	3-7

#### Section 4. Participant Accrual

4.1	Study Accrual Plan and Site-Specific Accrual Targets .....	4-1
4.2	Screening and Enrollment .....	4-2
	4.2.1 Definition of Screening .....	4-2
	4.2.2 Definition of Enrollment .....	4-3
	4.2.3 Screening and Enrollment Timeframe.....	4-3
	4.2.4 Screening and Enrollment Log.....	4-4
	4.2.5 Assignment of Participant ID Numbers .....	4-5
	4.2.6 HIV Testing.....	4-5
	4.2.7 Syphilis Testing.....	4-6
	4.2.8 Random Assignment .....	4-6
	4.2.8.1 Prescription Overview .....	4-7
	4.2.8.2 Participant-Specific Procedures.....	4-7
4.3	Product Use Instructions, First Product Use, and Adherence Counseling .....	4-8

#### Section 5. Informed Consent

5.1	Overview of Informed Consent Requirements and Procedures .....	5-1
5.2	Informed Consent for Screening .....	5-3
5.3	Informed Consent for Enrollment .....	5-3
5.4	Informed Consent for Specimen Storage and Possible Future Research Testing .....	5-3
5.5	Informed Consent Support Materials .....	5-5
	5.5.1 Comprehension Assessment.....	5-5
	5.5.2 Documenting the Informed Consent Process .....	5-7

## **Section 6. Participant Follow-up**

6.1	Study Follow-up Plan and Participant Retention Targets .....	6-1
6.2	Types of Follow-up Visits .....	6-1
6.3	Follow-up Visit Scheduling.....	6-2
6.3.1	Target Visit Dates.....	6-2
6.3.2	Visit Windows.....	6-2
6.3.3	Visits Conducted Over Multiple Days: “Split Visits” .....	6-5
6.3.4	Missed Visits .....	6-6
6.4	Follow-up Visit Procedures .....	6-6
6.5	Follow-up Visit Locations.....	6-6
6.6	Product Re-Supply during Follow-up .....	6-6
6.6.1	MTN-013/IPM 026 Vaginal Ring Request Slip.....	6-6
6.7	HIV Testing During Follow-Up.....	6-6
6.8	Modified Follow-up Procedures for Participants Who Become Infected with HIV .....	6-7
6.9	Modified Follow-up Procedures for Participants Who Become Pregnant .....	6-8
6.10	Modified Procedures for Participants Who Permanently Discontinue Product Use (IoR Discretion or Participant Volunteer) .....	6-9
6.11	Resumption of Study Participation After Voluntary Withdrawal .....	6-11
6.12	Study Exit Considerations .....	6-11
6.12.1	Participant Locator Information .....	6-12
6.12.2	HIV Counseling and Testing .....	6-12
6.12.3	AE Management and Documentation .....	6-12
6.12.4	Final Study Contact .....	6-12
6.12.5	Referral to Non-Study Service Providers .....	6-13
6.12.6	Early Termination .....	6-13
6.12.7	Post-Study Contact.....	6-13

## **Section 7. Visit Checklists**

7.1	Use of Visit Checklists .....	7-1
7.2	Sequence of Procedures.....	7-2

## **Section 8. Participant Retention**

8.1	Retention Definitions .....	8-1
8.2	Retention Requirements .....	8-1
8.3	Retention SOPs.....	8-2
8.4	Obtaining and Updating Locator Information.....	8-3
8.5	Retention Tips .....	8-3
8.6	Participants Who Voluntarily Discontinue Study Participation .....	8-4

## **Section 9. Study Product Considerations for Non-Pharmacy Staff**

9.1	Vaginal Ring (VR) Use Instructions .....	9-1
9.2	Dispensing Vaginal Rings .....	9-4
9.2.1	Dispensing of Study Product from Pharmacy .....	9-4
9.2.2	Dispensing of Study Product from Clinic Staff.....	9-4
9.3	Return of Study VR.....	9-5
9.3.1	Used VR Supplies .....	9-5
9.4	Vaginal Ring Request Slip .....	9-6
9.5	Product-Related Scenarios .....	9-6

## **Section 10. Clinical Considerations**

10.1	Baseline Medical/Menstrual History and Ascertainment of Concomitant Medications	10-1
10.1.1	Screening Visit .....	10-1
10.1.2	Enrollment Visit .....	10-2
10.1.3	Follow-up Visits .....	10-2
10.1.4	Ascertainment of Concomitant Medications .....	10-2
10.1.5	Pre-Existing Conditions .....	10-3
10.2	Physical Exams.....	10-4
10.3	Pelvic Exams .....	10-4
10.3.1	Detailed Overview of Pelvic Exams.....	10-4
10.3.2	Detailed Procedural Instructions .....	10-5
10.3.3	Order of Procedures.....	10-6
10.4	Pharmacokinetics Procedures.....	10-7
10.4.1	Blood Samples for Dapivirine and Maraviroc Levels.....	10-8
10.4.2	Vaginal Samples for Dapivirine and Maraviroc Levels .....	10-8
10.5	Documentation of Pelvic Examination Findings.....	10-9
10.6	Genital Bleeding Assessment.....	10-11
10.6.1	Participant Reports of Genital Bleeding.....	10-11
10.6.2	Clinician Assessment and Documentation of Genital Bleeding.....	10-11
10.6.3	Genital Bleeding Assessment for Pregnant Participants .....	10-15
10.6.4	Documentation of Genital Bleeding.....	10-15
10.7	STI/RTI Diagnosis .....	10-17
10.7.1	STI/RTI Treatment .....	10-18
10.7.2	Adverse Event Reporting Considerations .....	10-19
10.8	Pap Smear Management.....	10-19
10.9	Urinary Tract Infections .....	10-20
10.10	Product Use Management .....	10-21
10.10.1	Circumstances In Which Product Use Must Be Permanently Discontinued..	10-21
10.10.2	Circumstances In Which Product Use May Be Either Temporarily Held or Permanently Discontinued .....	10-21
10.11	Documentation of Product Use Management.....	10-21

## **Section 11. Adverse Event Reporting and Safety Monitoring**

11.1	Definitions and General Reporting Guidance .....	11-1
11.1.1	Adverse Event (AE) .....	11-1
11.1.2	Reporting Adverse Events.....	11-2
11.1.3	Serious Adverse Events (SAEs).....	11-3
11.1.4	Reporting Adverse Events in an Expedited Manner (EAE Reporting) .....	11-3
11.2	Adverse Event Terminology .....	11-6
11.3	Adverse Event Severity .....	11-6
11.4	Adverse Event Relationship to Study Product .....	11-7
11.5	Adverse Event Outcomes and Follow-Up Information.....	11-7
11.6	Reporting Recurrent Adverse Events .....	11-9
11.7	Social Harms .....	11-9
11.8	Safety Monitoring, Review, and Oversight.....	11-10
11.9	Safety Distributions from DAIDS .....	11-11

## Section 12. Laboratory Considerations

12.1	Overview and General Guidance.....	12-1
12.2	Specimen Labeling.....	12-6
12.3	Procedures for Specimens That Cannot be Evaluated.....	12-6
12.4	Use of LDMS.....	12-6
12.5	Urine Testing for Pregnancy and Urinary Tract Infection.....	12-10
	12.5.1 Specimen Collection.....	12-10
	12.5.2 Pregnancy Testing.....	12-10
	12.5.3 Dipstick Urinalysis.....	12-10
12.6	Blood Specimens for HIV testing, Hematology, Chemistries, Syphilis, Plasma Archive, Blood Dapivirine, Blood Maraviroc.....	12-11
	12.6.1 Specimen Collection and Initial Processing.....	12-11
	12.6.2 HIV Testing.....	12-11
	12.6.3 Hematology Testing.....	12-12
	12.6.4 Serum Chemistries.....	12-12
	12.6.5 Syphilis Testing.....	12-12
	12.6.6 Plasma Archive.....	12-13
	12.6.7 Blood Dapivirine and Maraviroc.....	12-13
12.7	Testing of Vaginal Specimens.....	12-14
	12.7.1 Vaginal pH.....	12-14
	12.7.2 Gram Stains on Vaginal Fluid.....	12-14
	12.7.3 Vaginal Swab for Quantitative Culture.....	12-15
	12.7.4 Shipping instructions to MTN NL.....	12-16
	12.7.5 Vaginal Fluid Wet Mount Testing for BV and yeast (Only if indicated).....	12-16
	12.7.6 Rapid Test for Trichomoniasis.....	12-17
	12.7.7 NAAT Chlamydia and Gonorrhea Testing.....	12-18
	12.7.8 Tear Test Strip for Vaginal PK Assessment.....	12-18
	12.7.9 Vaginal Swab for PD (Pharmacodynamics) and/or Biomarkers.....	12-20
	12.7.10 Vaginal Swab for Validation.....	12-20
12.8	Testing of Intravaginal Ring (VR).....	12-21
	12.8.1 Testing of Intravaginal Ring (VR) for Residual PK: UAB and Fenway Sites.....	12-21
	12.8.2 Testing of Intravaginal Ring (VR) for Biofilms (Pittsburgh site only).....	12-22
12.9	Testing of Cervical Specimens.....	12-23
	12.9.1 Cervical Biopsy.....	12-23
	12.9.2 Cervical Biopsies for PK analysis.....	12-23
	12.9.3 Cervical Biopsy for PD (HIV ex vivo challenge).....	12-24
	12.9.4 Papanicolaou (Pap) Test (* only if indicated).....	12-25

## Section 13. Data Collection

13.1	DataFax Overview.....	13-1
13.2	DataFax Form Completion.....	13-2
	13.2.1 General Guidelines.....	13-2
	13.2.2 How to Mark Response Boxes.....	13-3
	13.2.3 How to Record Numbers.....	13-3
	13.2.4 How to Record Dates.....	13-4
	13.2.5 How to Record Time.....	13-5
	13.2.6 Data Corrections and Additions.....	13-6
	13.2.7 How to Handle Missing and Unknown Data.....	13-7
13.3	Study-Specific Data Collection Information.....	13-7
	13.3.1 Participant ID numbers (PTIDs).....	13-7

13.3.2	Study Visit Timing .....	13-8
13.3.3	Visit Codes and Page Numbers .....	13-10
13.3.4	Staff Initials/Date .....	13-12
13.3.5	Case Report Form Completion Schedule .....	13-12
13.3.6	Site Review of DataFax Forms .....	13-17
13.3.7	Faxing DataFax Forms .....	13-18
13.3.8	Non-DataFax Forms .....	13-18
13.4	Form Supply and Storage .....	13-19
13.4.1	Form Supply .....	13-19
13.4.2	Form Storage .....	13-19
13.5	Completing Interviewer-administered Forms.....	13-19
13.6	Form Completion Instructions.....	13-19
13.7	Case Report Forms .....	13-20

## **Section 14. Data Communiqués**

## **Section 15. Study Reporting Plan**

15.1	Purpose of Reporting Plan.....	15-1
15.2	Study Reports .....	15-1
15.2.1	Data Quality Control (QC) Report .....	15-3
15.2.2	Clinical Data Quality Control (CQC) Queries .....	15-3
15.2.3	Unresolved Adverse Experiences Listing .....	15-3
15.2.4	Specimen Monitoring Report .....	15-3
15.2.5	Enrollment and Retention Report.....	15-3
15.2.6	Visit Adherence and Procedure Completion Report .....	15-3
15.2.7	Site Data Management Quality Report .....	15-4
15.2.8	Safety (PSRT) Reports .....	15-4
15.2.9	Network Lab Assay Results Report .....	15-4
15.2.10	Study Monitoring Committee Report.....	15-4

## **Section 16. Behavioral Measures**

16.1	Overview .....	16-1
16.1.1	Troubleshooting .....	16-1
16.2	Equipment Requirements and Set-up .....	16-2
16.2.1	Keyboard and Mouse Use .....	16-2
16.3	Data Collection Instruments .....	16-2
16.3.1	Baseline Questionnaire.....	16-2
16.3.2	Ring Adherence Questionnaire .....	16-3
16.3.3	Protocol Adherence Questionnaire.....	16-3
16.3.4	Acceptability Questionnaire .....	16-4
16.3.5	Semi-Structured Interview .....	16-4
16.3.6	Question-by-Question Instructions.....	16-5
16.4	Special cases and Technical issues.....	16-5
16.4.1	Hard Copy Back-up.....	16-5
16.4.2	Split or interrupted visits .....	16-5
16.4.3	Management of Errors on CASI.....	16-6
16.5	Staff Training .....	16-6

## **Section 17. Counseling Considerations**

17.1	HIV Pre and Post Test Counseling .....	17-1
17.2	Risk Reduction Counseling .....	17-1
17.3	Contraception Counseling .....	17-2
17.4	Study Product Adherence Counseling .....	17-3
	17.4.1 Study Product Use Adherence Counseling at Enrollment.....	17-3
	17.4.2 Study Product Use Adherence Counseling during Follow Up .....	17-5
	17.4.3 Product Use Instructions .....	17-5
17.5	Protocol Adherence Counseling .....	17-6
	17.5.1 Prohibited Practices .....	17-6
	17.5.2 Prohibited Medications.....	17-6